8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 19, 2022

NEOGEN CORPORATION

(Exact name of registrant as specified in its charter)

Michigan

0-17988

38-2367843

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


620 Lesher Place Lansing, Michigan		48912
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 517-372-9200

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

Title of each Class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.16 par value per share

NEOG

NASDAQ Global Select Market

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 19, 2022, Neogen Corporation (the “Registrant”) announced that Doug Jones was named Chief Operating Officer. In this newly created role, Jones will have responsibility for Neogen’s worldwide revenues and operations. Also on this date, Dr. Jason Lilly, Vice President, International Business, was given responsibility for the North American genomics operations on an interim basis. Dr. Lilly has extensive experience in Neogen’s Genomics business, including current oversight of four genomics laboratories outside of North America. Marylinn Munson, former Vice President, Genomics, has left the Company. Jerome Hagedorn, VP North American Operations, and Dr. Lilly will each report to Mr. Jones, and Mr. Jones will continue to report directly to John Adent, President and CEO.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


						NEOGEN CORPORATION
						(Registrant)
Date: April 21, 2022

						/s/ Steven J. Quinlan
						Steven J. Quinlan
						Vice President & CFO

Neogen Corporation filed SEC Form 8-K: Leadership Update